20/20 Biolabs, Inc.
Business
20/20 Biolabs develops and commercializes AI-powered laboratory-based blood tests for early detection and prevention of cancers and chronic diseases under the OneTest brand. The company offers OneTest for Cancer, a multi-cancer early detection test using protein tumor markers, and OneTest for Longevity, which measures inflammatory biomarkers associated with chronic disease. Both tests are performed in the company's CLIA-licensed, CAP-accredited laboratory in Gaithersburg, Maryland, and the company also operates a Clinical Laboratory Innovation Accelerator for diagnostics startups and maintains a legacy BioCheck field test for screening suspicious powders.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Revenues | 2 | 2 | |
| Cost of revenues | 1 | 1 | |
| Gross profit | 604,541 | 360,311 | |
| Sales, general and administrative | 3 | 5 | |
| Research and development | 592,569 | 1 | |
| Loss on impairment of fixed assets | — | 16,356 | |
| Total operating expenses | 4 | 6 | |
| Operating loss | −3 | −6 | |
| Interest expense | −156,207 | −12,646 | |
| Interest income | 21,399 | 79,467 | |
| Change in fair value of derivative liabilities | 7,737 | — | |
| Loss on issuance of convertible note | −280,764 | — | |
| Other (expense) income, net | −115 | 58,925 | |
| Total other (expense) income | −407,950 | 125,746 | |
| Provision for income taxes | — | — | |
| Net loss | −4 | −6 | |
| Basic net loss per common share (in Dollars per share) | −0.76 | −1.16 | |
| Diluted net loss per common share (in Dollars per share) | −0.76 | −1.16 | |
| Weighted-average common shares outstanding, basic (in Shares) | 5 | 5 | |
| Weighted-average common shares outstanding, diluted (in Shares) | 5 | 5 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 1 | 2 | — | |
| Accounts receivable, net | 199,954 | 135,272 | 68,834 | |
| Inventory | 116,217 | 47,164 | — | |
| Prepaid expenses and other current assets | 128,975 | 67,780 | — | |
| Total current assets | 1 | 2 | — | |
| License agreement, net | 271,143 | 293,643 | — | |
| Property and equipment, net | 56,677 | 116,669 | — | |
| Intangible assets, net | 202,264 | 205,529 | — | |
| Right-of-use asset, net | 605,289 | 772,385 | — | |
| Deferred offering costs | 2 | — | — | |
| Other assets | 23,057 | 161,957 | — | |
| Total assets | 4 | 4 | — | |
| Accounts payable | 868,545 | 372,303 | — | |
| Accrued liabilities | 785,784 | 346,622 | — | |
| Deferred revenue | 414,871 | 470,451 | — | |
| Derivative liability | 143,382 | — | — | |
| Convertible note | 74,611 | — | — | |
| Operating lease liability current | 175,948 | 165,702 | — | |
| Total current liabilities | 2 | 1 | — | |
| Convertible notes payable, net | 619,355 | — | — | |
| Deferred revenue long-term | 41,816 | 50,000 | — | |
| Derivative liabilities long-term | 543,545 | — | — | |
| Operating lease liability long term | 488,725 | 673,848 | — | |
| Total long-term liabilities | 2 | 723,848 | — | |
| Total liabilities | 4 | 2 | — | |
| Commitments and contingencies (Note 8) | — | — | — | |
| Common stock, $0.01 par value; 50,000,000 authorized; 5,442,249 and 4,823,125 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 54,422 | 48,231 | — | |
| Subscription receivable | — | −28,734 | — | |
| Additional paid-in capital | 33 | 31 | — | |
| Accumulated deficit | −33 | −30 | — | |
| Total stockholders (deficit) equity | −19,225 | 2 | 4 | |
| Total liabilities and stockholders equity | 4 | 4 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Depreciation and amortization | 63,257 | 116,035 | |
| Stock based compensation | 516,180 | 2 | |
| Amortization of license fees | 22,500 | 22,500 | |
| Amortization of right-of-use assets, net of liabilities | −7,781 | −2,778 | |
| Amortization of debt discount | 115,184 | 4,979 | |
| Change in fair value of derivative liability | −7,737 | — | |
| Accounts receivable | −64,682 | −66,438 | |
| Inventory | −69,052 | 13,504 | |
| Prepaid expenses and other assets | 77,705 | 215,002 | |
| Accounts payable | 496,242 | 12,025 | |
| Accrued liabilities | 419,263 | 172,352 | |
| Interest payable | 41,023 | 7,667 | |
| Deferred revenue | −63,765 | 265,580 | |
| Net cash used in operating activities | −2 | −3 | |
| Proceeds from issuance of convertible notes payable | 988,472 | — | |
| Proceeds from issuance of Series D preferred stock | 192,338 | 293,333 | |
| Proceeds from issuance of pre-delivery shares | 4,750 | — | |
| Deferred offering costs | −23,862 | — | |
| Net cash provided by financing activities | 1 | 293,333 | |
| Decrease in cash and cash equivalents | −758,022 | −2 | |
| Cash paid for interest | — | — | |
| Cash paid for income taxes | — | — | |
| Deferred offering costs issuance of common stock issued as offering costs | 1 | — | |
| Derivative liabilities recognized as debt discounts | 430,814 | — | |
| Conversion of convertible notes payable and accrued interest to common stock | — | 241,811 | |
| Subscription receivable - Issuance of series D preferred | — | 28,734 | |
| Officer forgiveness of accrued compensation | — | 58,415 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is 20/20 Biolabs, Inc.'s CIK number?
20/20 Biolabs, Inc.'s SEC CIK number is 0001139685 (1139685). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find 20/20 Biolabs, Inc.'s SEC filings?
All of 20/20 Biolabs, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did 20/20 Biolabs, Inc. last report earnings?
20/20 Biolabs, Inc. (AIDX) most recently filed an earnings 8-K with the SEC on May 20, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-26-059526). This is 20/20 Biolabs, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is 20/20 Biolabs, Inc.'s most recent earnings 8-K?
20/20 Biolabs, Inc.'s latest earnings 8-K (Item 2.02) was filed May 20, 2026 under accession 0001213900-26-059526. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View 20/20 Biolabs, Inc.'s latest earnings 8-K →
Look up any company's CIK number →